ClinicalTrials.gg
Active, not recruitingNCT02473536Updated Jan 16, 2026

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

A Phase 1/2 interventional study of Stereotactic ablative radiation therapy in Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by University of Texas Southwestern Medical Center · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Carcinoma, Renal Cell · University of Texas Southwestern Medical Center.

Started
2015
the only one that year
Phase 1/2
Only one
of the 10
Registered
1st of 10
by date

Among the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, this one is the only one that started in 2015, is the only one in phase 1/2, and was the 1st registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

To evaluate the safety and feasibility of pre-operative SABR of RCC IVC tumor thrombus.

To evaluate the effect of pre-operative SABR in RCC IVC tumor thrombus on relapse free survival at one year.

Read the detailed description

Stereotactic Ablative Radiation Therapy (SABR): 5 fractions of 8 Gy or 3 fractions of 12Gy. The concept of stereotactic radiosurgery involves tightly conforming dose of therapeutic radiation confined to a small region of the body. This results in eradication or ablation of the target tumor with sparing of surrounding normal tissues. The largest experience with stereotactic radiosurgery is for the treatment of intracranial tumors Neoadjuvant treatment of IVC-TT with SABR may decrease local recurrences and lower the likelihood of embolic complications and systemic metastasis.

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Radiographic evidence of renal cancer with IVC tumor thrombus
  2. Tumor thrombus must be ≥ level II (As per Mayo classification, it would be ≥ level I [Refer to NEVES, R. and ZINCKE, H. (1987), Surgical Treatment of Renal Cancer with Vena Cava Extension. British Journal of Urology, 59: 390-395. doi:10.1111/j.1464-410X.1987.tb04832.x])
  3. Patient eligible for SABR to the IVC tumor thrombus as decided by the treating radiation oncologist
  4. Patient eligible for IVC tumor thrombectomy as decided by the treating urologist
  5. Any number of disease is allowed in the Pilot phase of the trial

    • For Phase II, metastatic patients will be allowed only if all sites of metastasis has been treated either surgically or radio-surgically (If limited sites of metastasis are present, all of which can be resected during the nephrectomy, then the patient can be eligible)
  6. Age ≥ 18 years.
  7. Performance status 0-2
  8. Any serum Albumin is allowed, but ≥ 3.4 g/dL is strongly encouraged

    • Serum albumin \<3.4 is a significant predictor of peri-operative mortality(12)
  9. Any serum is allowed but serum AST ≤ 34 IU/L is strongly encouraged

    • Significant predictor of mortality in univariate but not multivariate analysis(12)
  10. Women of and men must agree to use adequate (hormonal such as birth control pills, patch or ring; Depo-Provera, Implanon or barrier method, such as condom or diaphragm used with a spermicide of birth control; abstinence) prior to study entry, for the duration of study treatment, and for 90 days following completion of radiation therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    10.1 A female of childbearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  11. Ability to understand and the willingness to sign a written .
  12. Subjects must be able to undergo either MRI or CT.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have had radiotherapy to a target within 3 cm of the IVC tumor thrombus.
  2. Subjects may have received any other agents or chemotherapy as long as they are eligible for SABR and surgery
  3. Subjects with should be excluded from this clinical trial unless all the are treated surgically or radio-surgically
  4. Subjects with a history of pulmonary embolism is excluded
  5. Subjects with a history of pulmonary hypertension is excluded
  6. Subjects must not be pregnant due to the potential for congenital abnormalities.
  7. for contrast-enhanced MRI as defined by the standard operating procedures of the Department of Radiology at UT Southwestern. Briefly, these include medically unstable; cardiac pacemaker; intracranial clips, metal implants; metal in the eyes; pregnant or nursing; claustrophobia; and impairment of the renal function with estimated (eGFR) \< 30 mL/min/1.73m2. Patients with one or more of these contraindications but eligible to undergo contrast-enhanced CT can participate in this study and will not receive an MRI
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Stereotactic ablative radiation therapy

    SABR

    Radiation: Stereotactic ablative radiation therapy

Interventions

  • RadiationStereotactic ablative radiation therapy

    SABR

06

What researchers measure

Primary outcomes

  1. To determine the feasibility of neoadjuvant SABR followed immediately by IVC tumor thrombectomy

    The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.

    Time frame: 90 days

  2. To determine the operative safety of neoadjuvant SABR followed immediately by IVC tumor thrombectomy

    The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.

    Time frame: 90 days

  3. Survival at one year

    Phase II To determine the relapse-free survival at one-year

    Time frame: ONE YEAR

Secondary outcomes

  1. Peri-operative morbidity

    To describe the associated peri-operative morbidity. Associated peri-operative morbidity is defined as grade\>2 side effects as assessed by NCI's CTCAE v4.0 toxicity within one year of surgery.

    Time frame: 90 days

  2. Adverse events post surgery

    To determine the associated adverse events within one year of surgery. Associated adverse events are any toxicity as defined by NCI's CTCAE v4.0 toxicity criteria for the first year post- surgery.

    Time frame: 1 year

  3. Recurrence free survival (1 year)

    To determine the 1 year recurrence free survival

    Time frame: 1 year

  4. Recurrence free survival overall

    To determine the recurrence free survival

    Time frame: 7 years

  5. Recurrence

    To determine the median time to recurrence

    Time frame: 7 years

  6. Pulmonary emboli

    To determine the rate of pulmonary emboli within one year of surgery. Pulmonary Emboli: Pulmonary embolus determined in patients that become symptomatic and as a result has radiographic evidence of pulmonary embolus on CT angio or V/Q scan.

    Time frame: 1 year

  7. Pulmonary metastasis

    To determine the rate of pulmonary metastasis. Pulmonary Metastasis: Any evidence of new lung metastasis \>1.0 cm • New lung nodules \>0.5cm will also be reported.

    Time frame: 7 years

  8. Systemic metastasis

    To determine the rate of systemic metastasis. Systemic Metastasis: Any evidence of new metastasis that is progressing on a second scan \> 6 weeks apart

    Time frame: 7 years

  9. Overall survival

    The rate of overall survival. Overall Survival: Time to death from the date of treatment start.

    Time frame: 7 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jan 2027, 139 months after the start.

Of 41 non-industry phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 132. This study's planned 139 months is above that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2015
First posted
Jun 16, 2015
StartActual
Jun 2015
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02473536
Responsible party
Raquibul Hannan (Associate Professor of Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jun 16, 2015
Start date
Jun 2015
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Raquibul Hannan, MD
principal investigator · UTSW

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion